BR9808720A - Carprofeno seletivo para cox-2 para tratamento de dor e inflamação em cães - Google Patents

Carprofeno seletivo para cox-2 para tratamento de dor e inflamação em cães

Info

Publication number
BR9808720A
BR9808720A BR9808720-7A BR9808720A BR9808720A BR 9808720 A BR9808720 A BR 9808720A BR 9808720 A BR9808720 A BR 9808720A BR 9808720 A BR9808720 A BR 9808720A
Authority
BR
Brazil
Prior art keywords
cox
activity
dogs
acids
carprofen
Prior art date
Application number
BR9808720-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Kristin Marie Lundy
Anthony Paul Ricketts
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9808720A publication Critical patent/BR9808720A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
BR9808720-7A 1997-05-05 1998-05-01 Carprofeno seletivo para cox-2 para tratamento de dor e inflamação em cães BR9808720A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4563597P 1997-05-05 1997-05-05
PCT/IB1998/000662 WO1998050033A1 (en) 1997-05-05 1998-05-01 Cox-2 selective carprofen for treating pain and inflammation in dogs

Publications (1)

Publication Number Publication Date
BR9808720A true BR9808720A (pt) 2000-07-11

Family

ID=21939053

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808720-7A BR9808720A (pt) 1997-05-05 1998-05-01 Carprofeno seletivo para cox-2 para tratamento de dor e inflamação em cães

Country Status (32)

Country Link
EP (1) EP0988034A1 (hr)
JP (1) JP2000513020A (hr)
KR (2) KR20010012300A (hr)
CN (1) CN1255059A (hr)
AP (1) AP9801234A0 (hr)
AR (2) AR011726A1 (hr)
AU (1) AU6932198A (hr)
BG (1) BG103852A (hr)
BR (1) BR9808720A (hr)
CA (1) CA2288759A1 (hr)
DZ (1) DZ2479A1 (hr)
EA (1) EA003696B1 (hr)
GT (1) GT199800063A (hr)
HR (1) HRP980244A2 (hr)
HU (1) HUP0001286A3 (hr)
ID (1) ID21311A (hr)
IL (1) IL132570A0 (hr)
IS (1) IS5220A (hr)
MA (1) MA26491A1 (hr)
NO (1) NO995389L (hr)
NZ (1) NZ500183A (hr)
OA (1) OA11213A (hr)
PA (1) PA8450601A1 (hr)
PE (1) PE72599A1 (hr)
PL (1) PL337003A1 (hr)
SK (1) SK148199A3 (hr)
TN (1) TNSN98059A1 (hr)
TW (1) TW590773B (hr)
UY (1) UY24989A1 (hr)
WO (1) WO1998050033A1 (hr)
YU (1) YU55899A (hr)
ZA (1) ZA983722B (hr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
AU2003204888B2 (en) * 1998-05-22 2005-07-28 Pfizer Products Inc. Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives
US6506785B2 (en) * 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
EP1123091A1 (en) * 1998-10-23 2001-08-16 Merck Frosst Canada & Co. Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
EP1637137A3 (en) * 1999-03-10 2006-07-05 G.D. Searle LLC Method and composition for administering a cyclooxygenase-2 inhibitor to animals
AU1592901A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
AU2001259974A1 (en) * 2000-05-15 2001-11-26 Merck Frosst Canada & Co Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
EA200802070A1 (ru) 2000-06-13 2009-06-30 Вайет Болеутоляющее и противовоспалительные составы, содержащие ингибиторы циклооксигеназы-2
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
WO2002012549A1 (en) 2000-08-07 2002-02-14 Vanderbilt University Compositions and methods for detecting and quantifying cox-2 activity and 2-arachidonylglycerol metabolites
AU2002354901A1 (en) * 2001-07-16 2003-03-03 Edward Hogestatt Compounds with analgesic, antipyretic and/or anti-inflammatory activity
ATE342722T1 (de) 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
KR100780983B1 (ko) * 2003-07-31 2007-11-30 파마시아 앤드 업존 캄파니 엘엘씨 소염제의 분산성 제제
EP1940380A2 (en) * 2005-05-20 2008-07-09 Pfizer Limited Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands
US9114071B2 (en) 2007-04-04 2015-08-25 Sigmoid Pharma Limited Oral pharmaceutical composition
JP2010527285A (ja) 2007-04-26 2010-08-12 シグモイド・ファーマ・リミテッド 複数のミニカプセルの製造
ES2649112T3 (es) 2009-05-18 2018-01-10 Sigmoid Pharma Limited Composición que comprende gotas de aceite
WO2011018504A2 (en) 2009-08-12 2011-02-17 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015134792A1 (en) 2014-03-06 2015-09-11 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
BR112017009510A2 (pt) 2014-11-07 2017-12-19 Sigmoid Pharma Ltd composições compreendendo ciclosporina
CN107106536A (zh) * 2015-01-09 2017-08-29 美洲豹动物健康公司 治疗伴侣动物的腹泻的方法
US20230174485A1 (en) * 2020-03-25 2023-06-08 Sri International Lipoxygenase inhibitors
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (ko) 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896145A (en) * 1972-07-24 1975-07-22 Hoffmann La Roche Carbazoles
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions

Also Published As

Publication number Publication date
AR039628A2 (es) 2005-03-02
PL337003A1 (en) 2000-07-31
CN1255059A (zh) 2000-05-31
HRP980244A2 (en) 1999-02-28
DZ2479A1 (fr) 2003-02-01
NZ500183A (en) 2002-04-26
KR20010012300A (ko) 2001-02-15
MA26491A1 (fr) 2004-12-20
OA11213A (en) 2003-07-14
BG103852A (en) 2000-06-30
CA2288759A1 (en) 1998-11-12
NO995389L (no) 2000-01-04
GT199800063A (es) 1999-10-26
EA199900895A1 (ru) 2000-06-26
HUP0001286A2 (hu) 2000-11-28
ID21311A (id) 1999-05-20
SK148199A3 (en) 2001-09-11
IS5220A (is) 1999-10-19
WO1998050033A1 (en) 1998-11-12
YU55899A (sh) 2003-08-29
TNSN98059A1 (fr) 2005-03-15
AR011726A1 (es) 2000-08-30
KR20040004406A (ko) 2004-01-13
ZA983722B (en) 1999-11-04
EA003696B1 (ru) 2003-08-28
TW590773B (en) 2004-06-11
HUP0001286A3 (en) 2000-12-28
NO995389D0 (no) 1999-11-04
PE72599A1 (es) 1999-08-12
UY24989A1 (es) 2001-10-25
IL132570A0 (en) 2001-03-19
AU6932198A (en) 1998-11-27
PA8450601A1 (es) 2000-05-24
AP9801234A0 (en) 1999-11-04
JP2000513020A (ja) 2000-10-03
EP0988034A1 (en) 2000-03-29

Similar Documents

Publication Publication Date Title
BR9808720A (pt) Carprofeno seletivo para cox-2 para tratamento de dor e inflamação em cães
Jayanthi et al. Methamphetamine downregulates striatal glutamate receptors via diverse epigenetic mechanisms
Kolbe et al. 4‐n‐butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation
SE9603408D0 (sv) Medical use
CY1107729T1 (el) Φαρμακευτικες συνθεσεις
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
NO963568D0 (no) Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse
PT944631E (pt) Novos derivados substituidos de pirazole para tratamento de doencas cardiovasculares
EA200200246A1 (ru) Композиция, содержащая нестероидное противовоспалительное средство (nsaid) и ингибитор киназы egfr, для лечения или ингибирования полипов в ободочной кишке и рака ободочной и прямой кишки
ATE369848T1 (de) Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
ATE234090T1 (de) Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz
ATE407676T1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
DZ3265A1 (fr) Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
PT815087E (pt) Derivados de fenilo trissubstituidos
PT1005460E (pt) Biossintese de inibidores de prostaglandina-endoperoxido h-sintase
BR9910539A (pt) Derivados de 2 - (2 - clorofenil) - 3,4 - dihidro - 2h - pirrol
Ventura-Martínez et al. Peripheral involvement of the nitric oxide–cGMP pathway in the indomethacin-induced antinociception in rat
Jain et al. Analgesic, anti‐inflammatory and ulcerogenic activity of a zinc‐naproxen complex in mice and rats
DK1154766T3 (da) Anvendelse af R-arylpropionsyre til fremstilling af lægemidler til behandling af sygdomme hos mennesker og dyr, hvor sygdommene kan påvirkes terapeutisk ved inhibering af aktiveringen af NF-kappa B
ATE345123T1 (de) Behandlung von angiogenesebezogenen krankheiten mit benzoyl phenylessigsäure derivaten
HUP0400886A2 (hu) Koleszteril-észter transzfer protein inhibitorok és fibrinsav-származékok kombinációi szív-érrendszeri indikációkhoz
HUP0300689A2 (hu) Eljárás és kompozíciók gyulladásos betegségek kezelésére
Belichard et al. Pharmacological and molecular evidence for kinin B1 receptor expression in urinary bladder of cyclophosphamide‐treated rats

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.